A Roche's Genentech Alzheimer’s disease therapy failed an important clinical trial. At the press conference that followed, the scientists involved parsed over what when wrong and what should happen next. We'll discuss this conference and dive into what scientists are saying about an Alzheimer's moonshot. But that's not all. During a panel discussion at the BIO conference, a Fierce journalist witnessed a controversial take on diversity—which led to a conversation on diversity in biotech. Lastly, we'll take a close look at the top winners in pharma, health and wellness at the Cannes Lions International Festival of Creativity.
To learn more about the topics in this episode:
- Will we ever land the Alzheimer's moonshot? Genentech's crenezumab partners reflect on failure
- Another knock back for amyloid: Roche's approach to presymptomatic Alzheimer's ends in failure
- BIO: 'Diversity candidates' and knowledge 'shortfalls': Women in biotech say 'I'm here to do my job' despite toxic tropes
- Bausch Health pulls the plug on Solta Medical IPO and 3-way company split
- FDA signs off on Pfizer, Moderna COVID-19 vaccines for kids 6 months and older
- Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push
- Hot on Alnylam's heels, AstraZeneca racks up phase 3 win for Ionis-partnered rare disease drug
- Big Pharmas lose out at Cannes Lions as VMLY&R sweeps health categories with campaigns for Dell and Maxx Flash
- Winning agency behind Cannes Lions says its double health Grand Prix win shows a major shift in thinking
- Fierce Biotech NextGen Virtual Event
The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.